110 related articles for article (PubMed ID: 37741780)
1. Is surgical treatment of hepatocellular carcinoma at high-volume centers worth the additional cost?
Shaikh CF; Woldesenbet S; Munir MM; Lima HA; Moazzam Z; Endo Y; Alaimo L; Azap L; Yang J; Katayama E; Dawood Z; Pawlik TM
Surgery; 2024 Mar; 175(3):629-636. PubMed ID: 37741780
[TBL] [Abstract][Full Text] [Related]
2. Impact of Facility Type and Surgical Volume on 10-Year Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma.
Chapman BC; Paniccia A; Hosokawa PW; Henderson WG; Overbey DM; Messersmith W; McCarter MD; Gleisner A; Edil BH; Schulick RD; Gajdos C
J Am Coll Surg; 2017 Mar; 224(3):362-372. PubMed ID: 27923615
[TBL] [Abstract][Full Text] [Related]
3. Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis.
Tsilimigras DI; Hyer JM; Diaz A; Moris D; Abbas A; Dillhoff M; Cloyd JM; Ejaz A; Beane JD; Tsung A; Pawlik TM
Am J Surg; 2021 Sep; 222(3):570-576. PubMed ID: 33485619
[TBL] [Abstract][Full Text] [Related]
4. Cost of Major Complications After Liver Resection in the United States: Are High-volume Centers Cost-effective?
Idrees JJ; Johnston FM; Canner JK; Dillhoff M; Schmidt C; Haut ER; Pawlik TM
Ann Surg; 2019 Mar; 269(3):503-510. PubMed ID: 29232212
[TBL] [Abstract][Full Text] [Related]
5. Referral patterns between high- and low-volume centers and associations with uterine cancer treatment and survival: a population-based study of Medicare, Medicaid, and privately insured women.
Doll KM; Meng K; Gehrig PA; Brewster WR; Meyer AM
Am J Obstet Gynecol; 2016 Oct; 215(4):447.e1-447.e13. PubMed ID: 27130238
[TBL] [Abstract][Full Text] [Related]
6. What Is the Value of Undergoing Surgery for Spinal Metastases at Dedicated Cancer Centers?
Malik AT; Khan SN; Voskuil RT; Alexander JH; Drain JP; Scharschmidt TJ
Clin Orthop Relat Res; 2021 Jun; 479(6):1311-1319. PubMed ID: 33543875
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of robotic-arm assisted total knee arthroplasty.
Hua Y; Salcedo J
PLoS One; 2022; 17(11):e0277980. PubMed ID: 36441807
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare.
Parikh ND; Marshall VD; Green M; Lawrence TS; Razumilava N; Owen D; Singal AG; Feng M
J Med Imaging Radiat Oncol; 2018 Oct; 62(5):673-681. PubMed ID: 29877615
[TBL] [Abstract][Full Text] [Related]
9. Dedicated Perioperative Hip Fracture Comanagement Programs are Cost-effective in High-volume Centers: An Economic Analysis.
Swart E; Vasudeva E; Makhni EC; Macaulay W; Bozic KJ
Clin Orthop Relat Res; 2016 Jan; 474(1):222-33. PubMed ID: 26260393
[TBL] [Abstract][Full Text] [Related]
10. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
[TBL] [Abstract][Full Text] [Related]
11. Improved outcomes for patients with cerebrovascular malformations at high-volume centers: the impact of surgeon and hospital volume in the United States, 2000-2009.
Davies JM; Lawton MT
J Neurosurg; 2017 Jul; 127(1):69-80. PubMed ID: 27739942
[TBL] [Abstract][Full Text] [Related]
12. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.
Shaya FT; Breunig IM; Seal B; Mullins CD; Chirikov VV; Hanna N
Pharmacoeconomics; 2014 Jan; 32(1):63-74. PubMed ID: 24293197
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Sanoff HK; Chang Y; Lund JL; O'Neil BH; Dusetzina SB
Oncologist; 2016 Sep; 21(9):1113-20. PubMed ID: 27185615
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma: Impact of academic setting and hospital volume on patient survival.
Uhlig J; Sellers CM; Khan SA; Cha C; Kim HS
Surg Oncol; 2019 Dec; 31():111-118. PubMed ID: 31654956
[TBL] [Abstract][Full Text] [Related]
16. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.
Marqueen KE; Kim E; Ang C; Mazumdar M; Buckstein M; Ferket BS
JCO Oncol Pract; 2021 Feb; 17(2):e266-e277. PubMed ID: 33417490
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.
Lim KC; Wang VW; Siddiqui FJ; Shi L; Chan ES; Oh HC; Tan SB; Chow PK
Hepatology; 2015 Jan; 61(1):227-37. PubMed ID: 24638991
[TBL] [Abstract][Full Text] [Related]
19. Combined Hepatopancreaticobiliary Volume and Hepatectomy Outcomes in Hepatocellular Carcinoma Patients at Low-Volume Liver Centers.
de Geus SW; Woods AP; Papageorge MV; Zheng J; Ng SC; McAneny D; Sachs TE; Tseng JF
J Am Coll Surg; 2021 Jun; 232(6):864-871. PubMed ID: 33640522
[TBL] [Abstract][Full Text] [Related]
20. Association of social vulnerability with the use of high-volume and Magnet recognition hospitals for hepatopancreatic cancer surgery.
Diaz A; Hyer JM; Azap R; Tsilimigras D; Pawlik TM
Surgery; 2021 Aug; 170(2):571-578. PubMed ID: 33775393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
